Last reviewed · How we verify
DAXXIFY
Daxxify is a small molecule developed by Revance Therapeutics, Inc. Its mechanism of action and target are unknown, and it has not been approved by the FDA for any indications. As a small molecule, it is a chemically synthesized compound. The commercial status of Daxxify is unclear, and it is not yet available as a generic medication. Further research is needed to determine its safety and efficacy.
At a glance
| Generic name | DAXXIFY |
|---|---|
| Also known as | DAXI |
| Sponsor | Revance Therapeutics, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of all botulinum toxin products, including DAXXIFY, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, an unapproved use for DAXXIFY, but symptoms can also
Common side effects
- Headache
- Injection site pain
- Injection site erythema
- Injection site oedema
- Eyelid ptosis
- Edema
- Erythema
- Injection site bruising
- Facial paresis
- Muscular weakness
- Upper respiratory tract infection
- Injection site papule
Serious adverse events
- Spread of toxin effect
- Hypersensitivity reactions
- Cardiovascular system adverse reactions
- Increased neuromuscular compromise
- Dysphagia
- Breathing difficulties
Key clinical trials
- Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm (PHASE4)
- Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines (PHASE2)
- DaxibotulinimtoxinA for Treatment of Platysmal Neck Bands (PHASE4)
- Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DAXXIFY CI brief — competitive landscape report
- DAXXIFY updates RSS · CI watch RSS
- Revance Therapeutics, Inc. portfolio CI